Help You Invest

TCR2 Therapeutics (NASDAQ: TCRR) reviewed 10-15-2020 Market Cap: $689 Million (USD)                Share Price: $20.70 (USD) Shares outstanding: 33,344,021 as of 3 Aug 2020 Cash & cash equivalents: $49.7 M (USD) as of 30 Jun 2020 Debt:  None. Company funds via sales of common and preferred stock Insiders: Own 5.6%                          Institutional:

VIR Biotechnology Inc (NASDAQ: VIR) reviewed 10-15-2020 Market Cap: $5.0 Billion (USD)                   Share Price: $41.26 (USD) Shares outstanding: 117,727,086 at 30 Jun 2020 Cash & cash equivalents: $371.78 Million (USD) at 30 Jun 2020 Debt: Nil. [Net Liabilities stated as $108 Million (USD) at 30 Jun 2020] Insiders: Own 14.5%                       

Fate Therapeutics (NASDAQ: FATE) reviewed 10-14-2020 Market Cap: $4.1 Billion (USD)                   Share Price: $46.96 (USD) Shares outstanding: 86,802,162 Cash & cash equivalents: $433 Million (USD) at 30 Jun 2020 Debt:  None stated on the balance sheet Insiders: 2%        Institutional: 221 holders own 96% of the float Website: fatetherapeutics.com Investor Presentations:

Editas Medicine (NASDAQ: EDIT) reviewed 10-14-2020 Market Cap: $2.0 Billion (USD)   Share Price: $32.16 (USD) Shares outstanding: 62,103,649 Cash & cash equivalents: $485.8 M (USD) as of 30 Jun 2020 Debt:  None stated on the balance sheet Insiders: 2.4%                    Institutional: 291 holders own approx. 76% of the float Website: editasmedicine.com

BioNTech SE (NASDAQ: BNTX) reviewed 10-14-2020 Market Cap: $20.2 Billion (USD)                 Share Price: $86.86 (USD) Shares outstanding: 232,304,000 Cash & cash equivalents: $519 M (Euro) at 30 June 2020 Debt:  $19.45 M (Euro) via Deutsche Bank AG Insiders: 1.26%                  Institutional: 36 holders own approx. 4% of the float Website: biontech.de

Wallbridge Mining (TSX: WM) (OTC: WLBMF) reviewed 10-14-2020 Market Cap:       $422 Million (USD)          Share Price:        $0.72 (USD) Shares outstanding: 586,997,997 at 31 Dec 2019 Cash:  $42.5 Million (USD) at 30 Jun 2020 Debt: Nil as of 30 Jun 2020 Current operations: Exploration & Drilling Insider holdings: 35%.    Institutional: 7 holders

Novavax (NASDAQ: NVAX) reviewed 10-14-2020 Market Cap: $7.23 Billion (USD)                 Share Price: $118.00 (USD) Shares outstanding: 61,262,632 as of 30 Jun 2020 Cash & cash equivalents: $424,395 M (USD) as of 30 Jun 2020 Debt:     $323,321 M (USD) via Convertible notes Insiders: Low      Institutional: 36 holders own approx. 14%